ProShares S&P Kensho Cleantech ETF (ARCA: CTEX)

最新ニュース ProShares S&P Kensho Cleantech ETF (ARCA:CTEX)

Technology

Industrials

Utilities

Other

Consumer Cyclical

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the Index. The Index selects companies focused on building the technologies or products that enable the generation of clean energy, such as solar, wind, geothermal, hydrogen, and hydroelectric. The Index includes companies focused on building technologies or products that enable generation of energy in a clean manner.

Sunnova Energy International Incorporation Com

Sunrun Inc

American Superconductor Corp

Altus Power Inc

Ge Vernova Inc

Arcosa Inc

Ormat Technologies Inc

Canadian Solar Inc

Nextracker Inc

Enphase Energy Inc Common Stock

Proshares S&P Kensho Cleantech ETF

ProShares S&P Kensho Cleantech ETF

News

Guidance

CYRX

CryoPort Sees FY25 Revenue $240M-$250M vs $244.747M Est.

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly losses of $(0.02) per share. This is a 81.82 percent increase over losses of $(0.11) per share from the same period last year. The company reported $10.44 million in sales this quarter. This is a 11.58 percent increase over sales of $9.35 million the same period last year.

Earnings

CPIX

Cumberland Q4 Adj EPS $(0.02) Up From $(0.11) YoY, Sales $10.44M Up From $9.35M YoY

CRWD

CrowdStrike Holdings Sees FY26 Adj. EPS $3.33-$3.45 Vs $4.42 Est.; Revenue $4.743B-$4.805B Vs $4.769B Est.

Earnings Beats

Earnings Misses

SCOR

comScore Q4 2024 GAAP EPS $(0.27)

CrowdStrike Holdings Sees Q1 Adj. EPS $0.64-$0.66 Vs $0.95 Est.; Revenue $1.100B-$1.106B Vs $1.106B Est.

AVAV

AeroVironment Sees FY25 Adj. EPS $2.92-$3.13 Vs $3.45 Est; Revenue $780M-$795M Vs $821.4M Est.

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.26 per share. This is a 39.53 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $37.42 million which missed the analyst consensus estimate of $41.00 million by 8.74 percent. This is a 16.01 percent decrease over sales of $44.55 million the same period last year.

GIFI

Gulf Island Fabrication Q4 GAAP EPS $0.26 Down From $0.43 YoY, Sales $37.42M Miss $41.00M Estimate

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) sees FY2025 sales of $535.000 million-$565.000 million vs $528.94 million analyst estimate.

SWIM

Latham Group Sees FY2025 Sales $535.000M-$565.000M vs $528.94M Est

CryoPort Q4 2024 GAAP EPS $(0.42) Misses $(0.29) Estimate, Sales $59.532M Beat $58.548M Estimate

2025 Guidance and Select Milestones
<ul>
<li>Total net revenues for 2025 are estimated to be between $345 million and $355 million, which represents 30% to 33% growth from 2024 results. Evolysse&#x2122; and Estyme&#xAE; injectable hyaluronic acid (HA) gels are anticipated to contribute 8-10% of total revenue for the full-year 2025.</li>
<li>Non-GAAP operating expenses for 2025 are estimated to be between $230 million and $240 million, driven primarily by continued investments in expanding Jeuveau&#xAE; in the U.S., scaling Nuceiva&#xAE; internationally, and supporting the launch for Evolysse&#x2122; Form and Evolysse&#x2122; Smooth injectable HA gels.</li>
<li>Evolus expects to achieve positive non-GAAP operating income on a consolidated basis for the full-year 2025. Non-GAAP operating income is anticipated to be achieved after the launch of Evolysse&#x2122; Form and Evolysse&#x2122; Smooth injectable HA gels in the U.S., with investments continuing to ramp in Q1 2025 and revenue contribution weighted toward the second half of the year, resulting in our non-GAAP operating income being concentrated in Q4 2025.</li>
<li>Evolus plans to launch Evolysse&#x2122; Form and Evolysse&#x2122; Smooth in the U.S. market in Q2 2025 following their U.S. Food and Drug Administration (FDA) approval in February 2025. The U.S. commercial launch of these first two injectable HA gels is expected to be followed by Evolysse&#x2122; Sculpt in 2026, and Evolysse&#x2122; Lips in 2027.</li>
<li>Evolus is also introducing Estyme&#xAE; through a limited experience program with select physician partners in Europe, to continue to expand global experience with the product's performance. A broader European launch remains on track for the second half of 2025.</li>
<li>The company projects its total net revenue can reach at least $700 million by 2028, a compound annual growth rate of 27% from 2024, based on the combination of its existing aesthetic neurotoxin business and anticipated launch of the Evolysse&#x2122; and Estyme&#xAE; injectable HA gels beginning in 2025.</li>
<li>Evolus expects to achieve non-GAAP operating income margins of at least 20% by 2028 by leveraging its highly synergistic, existing infrastructure.</li>
</ul>

EOLS

Evolus Sees FY25 Revenue $345M-$355M Vs $351.29M Est.

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.09) by 88.89 percent. The company reported quarterly sales of $87.27 million which beat the analyst consensus estimate of $85.37 million by 2.23 percent. This is a 3.96 percent decrease over sales of $90.87 million the same period last year.

Latham Group Q4 Adj $(0.17) Misses $(0.09) Estimate, Sales $87.27M Beat $85.37M Estimate

The Company also expects its annual set deployment to be approximately $15.0 million and expects to generate $15.0 million to $17.0 million of adjusted EBITDA for full year 2025.

KIDS

OrthoPediatrics Expects 2025 Revenue Of $235M - $242M (Est $239.78M), Representing Growth Of 15% - 18% YoY

Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) reported quarterly sales of $55.80 million which beat the analyst consensus estimate of $47.88 million by 16.53 percent. This is a 66.67 percent decrease over sales of $167.40 million the same period last year.

STEM

Stem Q4 Sales $55.80M Beat $47.88M Estimate

AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.63 by 52.38 percent. This is a 52.38 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $167.600 million which missed the analyst consensus estimate of $196.371 million by 14.65 percent. This is a 10.17 percent decrease over sales of $186.578 million the same period last year.

AeroVironment Q3 2025 Adj. EPS $0.30 Misses $0.63 Estimate, Sales $167.600M Miss $196.371M Estimate

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares traded higher on Tuesday, reversing earlier losses as investors assess the potential impact of <a href="https://www.benzinga.com/news/large-cap/25/03/44121022/trumps-25-tariffs-on-auto-imports-are-worth-the-short-term-pain-says-ohio-gop-senator">new U.S. tariffs.</a>
What To Know: The tariffs, which have taken effect, impose 25% duties on most imports from Canada and Mexico and raise Chinese import duties to 20%. These measures apply to approximately $1.5 trillion in annual imports. While the auto industry faces substantial risks from higher costs and supply chain disruptions, the technology sector, including Nvidia, is responding with resilience.
NVIDIA's gains come despite broader market weakness, as investors focus on the company's strong position in the AI and semiconductor sectors. Concerns over rising consumer prices, particularly for goods like fresh produce, remain a factor in the market's volatility. Target CEO Brian Cornell warned that consumers would see <a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">price increases</a> within days due to the tariffs.
The tariff developments have also sparked political reactions. Ohio Republican Senator Bernie Moreno supports the measures, arguing that the <a href="https://www.benzinga.com/news/large-cap/25/03/44121022/trumps-25-tariffs-on-auto-imports-are-worth-the-short-term-pain-says-ohio-gop-senator">short-term economic pain is necessary </a>to address issues like border security and drug trafficking. Meanwhile, Canadian Prime Minister Justin Trudeau has announced retaliatory 25% tariffs on U.S. goods, further escalating trade tensions.
NVDA Price Action: Nvidia shares were up 1.69% to $115.99 on Tuesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04151715/Screenshot-2025-03-04-at-15.16.50-1024x532.png" alt="" class="wp-image-808932" style="width:371px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04151715/Screenshot-2025-03-04-at-15.16.50-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04151715/Screenshot-2025-03-04-at-15.16.50-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04151715/Screenshot-2025-03-04-at-15.16.50-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04151715/Screenshot-2025-03-04-at-15.16.50.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44118620/whats-driving-markets-tuesday">Stocks Drop As Trade War Escalates: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image Via Shutterstock.

Movers

NVDA

NVIDIA Stock Rises As Investors Weigh US Tariffs: What's Going On?

First Quarter of Fiscal 2026 Guidance
For the first fiscal quarter ending April 30, 2025, ChargePoint expects revenue of $95 million to $105 million.
ChargePoint remains committed to its plans of achieving positive non-GAAP Adjusted EBITDA during a quarter in fiscal year 2026.
ChargePoint is not able to present a reconciliation of its forward-looking non-GAAP Adjusted EBITDA goal to the corresponding GAAP measure because certain potential future adjustments, which may be significant and may include, among other items, stock-based compensation expense, are uncertain or out of its control, or cannot be reasonably predicted without unreasonable effort. The actual amounts of such reconciling items could have a significant impact on ChargePoint's GAAP Net Loss.
 &nbsp;

CHPT

ChargePoint Sees Q1 Revenue $95M-$105M Vs $101.53M

Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.37 by 16.22 percent. This is a 28.33 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $56.25 million which beat the analyst consensus estimate of $53.66 million by 4.84 percent. This is a 8.17 percent increase over sales of $52.01 million the same period last year.

MFIN

Medallion Finl Q4 GAAP EPS $0.43 Beats $0.37 Estimate, Sales $56.25M Beat $53.66M Estimate

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.85 by 21.18 percent. This is a 8.42 percent increase over earnings of $0.95 per share from the same period last year. The company reported quarterly sales of $1.058 which missed the analyst consensus estimate of $1.032 billion by 100.00 percent. This is a 100.00 percent decrease over sales of $845.335 million the same period last year.

CrowdStrike Holdings Q4 2025 Adj. EPS $1.03 Beats $0.85 Estimate, Sales $1.058 Miss $1.032B Estimate

Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 50 percent. This is a 20 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $209.31 million which missed the analyst consensus estimate of $216.47 million by 3.31 percent. This is a 9.49 percent decrease over sales of $231.25 million the same period last year.

CRCT

Cricut Q4 EPS $0.06 Beats $0.04 Estimate, Sales $209.31M Miss $216.47M Estimate

Stock Split

COKE

Coca-Cola Consolidated Board Approves 10-for-1 Stock Split

Comments

ProShares S&P Kensho Cleantech ETF

ニュース

最新ニュース ProShares S&P Kensho Cleantech ETF (ARCA:CTEX)

ニュース

パートナーシップ

ベンジンガ・グローバル